Abstract : Thyroid cancer is one of the fastest increasing cancers in recent years, with a 14.51 percent annual growth. It has been demonstrated that there is a link between several biomarkers and thyroid cancer progression. The goal of this study was to look at Galectin-3 (Gal-3) and liver function test(LFT); (AST, ALT, ALP) values in thyroid cancer patients. In the current study, (A hundred and forty-five) participants were separated into three groups: Group1: (sixty malignant thyroid gland patients), Group2: (thirty-five benign thyroid gland patients), and Group3: (fifty healthy control individuals as a control group). From November 2021 to February 2022, the patients were treated at the AL-Amal oncology Hospital in Baghdad, Iraq. Serum Gal-3 levels and liver function tests were measured in the study groups. Was to detection the levels of Galectin-3 levels biomarker and liver function test (AST, ALT, ALP) in serum of patients with thyroid tumor (malignant and benign) and compared to healthy as control, and measure by using ELISA techniques. The results showed that Gal-3 and LFT are significant difference in patients with malignant thyroid gland differ significantly from those in the control and benign tumor groups at (P<0.01). In the current research, Serum Galectin-3 levels were statistically higher in individuals with cancerous nodules than in benign and healthy controls. Furthermore, when compared to benign and healthy controls, LFT levels in patients with malignant nodules are statistically significantly higher.